CJC-1295 and Gabapentin Interaction: What You Need to Know

CJC-1295 (also sold under the research name "modified GRF 1-29" or "CJC-1295 without DAC") is a compounded growth hormone-releasing hormone (GHRH) analogue used off-label to stimulate endogenous growth hormone release. It is not an FDA-approved drug; it is prepared under 503A pharmacy compounding rules and has no approved New Drug Application. Gabapentin (Neurontin, Gralise, Horizant) is an FDA-approved anticonvulsant and gabapentinoid used on-label for partial seizures, postherpetic neuralgia, and restless legs syndrome, and off-label for neuropathic pain, anxiety, and insomnia. This article is about combining these two specific agents, not about CJC-1295 combined with other peptides or about pregabalin.

No published trial has studied CJC-1295 and gabapentin together. The core, verifiable answer is this: the two drugs do not share a metabolic clearance pathway, so a classic pharmacokinetic interaction (one drug raising or lowering the blood level of the other through liver enzymes) is not expected. The realistic concern is pharmacodynamic, both agents can independently affect central nervous system arousal and, through separate mechanisms, kidney function, and that overlap has not been tested in combination, only inferred from each drug's individual pharmacology.

The direct answer

CJC-1295 and gabapentin have no known pharmacokinetic interaction: neither is metabolized by hepatic CYP450 enzymes or P-glycoprotein, so neither is expected to change the other's blood concentration through that route. The plausible concern is additive central nervous system depression, since gabapentin is a labeled cause of somnolence and dizziness and GHRH signaling is mechanistically linked to deeper slow-wave sleep, plus a theoretical, unstudied renal interaction because growth hormone can raise glomerular filtration rate and gabapentin is cleared entirely by the kidneys. No randomized trial, case series, or pharmacokinetic study of the combination exists as of this writing, so all of the above is mechanistic reasoning, not direct evidence.

How each drug works, and why that matters for this pairing

CJC-1295 binds the pituitary GHRH receptor and drives pulsatile release of endogenous growth hormone (GH). Compounded protocols typically use doses in the range of 100 to 300 mcg subcutaneously, often timed before sleep to coincide with the body's natural nocturnal GH pulse. As a 30-amino-acid peptide, it is degraded by proteolytic enzymes, not by liver CYP450 enzymes, and no P-glycoprotein interaction has been described in the published literature. GH itself raises IGF-1, promotes lipolysis, and increases glomerular filtration rate (GFR), a detail that becomes relevant only because of what happens next with gabapentin.

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn and elsewhere in the CNS, reducing excitatory neurotransmitter release. It undergoes no hepatic metabolism and is excreted unchanged by the kidneys, with a half-life of roughly 5 to 7 hours in adults with normal renal function. Because its clearance depends entirely on renal filtration, anything that meaningfully changes GFR could, in principle, change gabapentin's steady-state blood level over time, which is the indirect link back to CJC-1295.

Is there a pharmacokinetic interaction?

Not through the usual route. Neither drug uses CYP450 enzymes, and no P-glycoprotein interaction has been reported for CJC-1295, so a classic metabolic drug-drug interaction is not expected between these two agents.

There is, however, an indirect and unstudied pathway worth flagging. Growth hormone replacement has been reported to increase GFR in GH-deficient adults on long-term recombinant GH therapy. Whether a compounded GHRH secretagogue like CJC-1295 produces a comparable, clinically meaningful GFR change in people who are not GH-deficient has not been established, and no study has measured whether that translates into a real-world shift in gabapentin exposure. The direction of the theoretical effect is that gabapentin clearance could increase modestly, which would tend to lower gabapentin blood levels rather than raise them, the opposite of a typical toxicity concern, but still relevant for a patient whose gabapentin dose was carefully titrated for seizure control. This should be treated as a hypothesis to monitor, not an established effect.

The reverse scenario is more clinically settled: patients with reduced kidney function accumulate gabapentin regardless of CJC-1295 use, and gabapentin's FDA label calls for reduced dosing as creatinine clearance falls. Anyone with chronic kidney disease who is considering adding a GH secretagogue should have that discussed explicitly with the prescriber managing their gabapentin, because both drugs now touch the same organ system.

Is there a pharmacodynamic (sedation) interaction?

This is the part of the picture with the clearest clinical relevance, even without a combination trial.

Gabapentin is a labeled cause of dose-dependent somnolence, dizziness, and ataMore ataxia, and these effects are well described as increasing when gabapentin is combined with other CNS-active drugs. CJC-1295 is not classified as a CNS depressant, but GHRH signaling has a documented role in promoting slow-wave (non-REM) sleep in animal studies. Whether compounded CJC-1295 at typical human doses produces a measurable sedating or sleep-deepening effect in people has not been tested in a controlled human trial; the mechanism is biologically plausible, not confirmed.

The practical concern is timing. Most CJC-1295 protocols call for a pre-sleep injection to amplify the natural nocturnal GH pulse. A patient who also takes gabapentin at bedtime is layering two agents with independent, mechanistically plausible sedating pathways onto the same few hours. The FDA has separately warned that gabapentinoids as a class carry a risk of serious breathing problems, particularly in combination with other CNS depressants or in patients with pre-existing respiratory compromise (a 2019 FDA drug safety communication on gabapentinoids). CJC-1295 is not named in that communication and has not been formally evaluated for this risk, but the same physiological logic, anything that deepens sleep or blunts arousal threshold worsens the same setting, applies to any additional sedating or sleep-promoting agent layered on top of a gabapentinoid.

Patients with untreated obstructive sleep apnea (OSA) deserve specific caution. GH therapy can worsen or unmask OSA in some individuals, and OSA is already a common reason clinicians pause or avoid GH-stimulating therapy. Adding a gabapentinoid to that picture compounds an already-recognized respiratory risk factor rather than introducing an entirely new one.

Who is at higher risk if these are combined?

• Age over 65, where slower baseline renal clearance and greater CNS sensitivity to sedatives are both well established for gabapentin independent of any peptide use.
• Chronic kidney disease with creatinine clearance below the threshold where gabapentin dosing must be reduced per its label.
• Concurrent use of opioids, benzodiazepines, muscle relaxants, or other sedating medications, which is the clearest, best-established driver of additive CNS depression with gabapentin.
• Untreated or undertreated obstructive sleep apnea.
• Same-evening alcohol use, since alcohol independently suppresses GH response to GHRH stimulation and independently worsens gabapentin's sedating effects, two separate, better-established interactions that compound each other around the same drinking occasion.

A younger patient with normal kidney function, no other CNS depressants, no OSA, and a daytime gabapentin schedule presents a materially lower-risk picture. Separating a bedtime CJC-1295 injection from an evening gabapentin dose by several hours reduces, but does not eliminate, the overlap.

Evidence-status interaction assessment

Reducing risk if a clinician decides to combine them

Separating the two agents in time is the simplest available step. Shifting CJC-1295 to a morning injection removes direct overlap with a bedtime gabapentin dose, though morning GH pulses are smaller than nocturnal ones and this may modestly reduce the intended effect of the peptide. Alternatively, moving the last gabapentin dose earlier in the evening allows more of gabapentin's roughly 5-to-7-hour half-life to elapse before a pre-sleep peptide injection.

For patients with reduced kidney function, gabapentin's FDA label specifies reduced dosing as creatinine clearance falls; the exact dose bands should be confirmed against the current label rather than assumed, since labeling can be updated. If a patient's renal function appears to be improving over months of GH secretagogue use, the prescriber managing gabapentin should be told, because a previously stable gabapentin dose could theoretically need adjustment to maintain the same clinical effect, the reverse of a typical toxicity concern, and equally worth tracking.

What the guidelines actually say

No clinical guideline from the FDA, the Endocrine Society, or the American Association of Clinical Endocrinology addresses CJC-1295 specifically, because it is a compounded peptide without an approved New Drug Application. The closest applicable guidance is indirect: the Endocrine Society's clinical practice guideline on adult GH deficiency addresses recombinant GH (somatropin), not GHRH secretagogues, and its cautions around sleep apnea and GH therapy are commonly extended by peptide prescribers to GHRH analogues as a matter of clinical judgment rather than direct guideline coverage. Readers should treat any specific wording attributed to that guideline as needing direct verification against the current published version rather than relying on a paraphrase here.

Gabapentin's FDA-approved labeling does address CNS depression risk directly and should be the primary reference for anything specific about gabapentin's sedation profile, dosing by renal function, or its respiratory depression warning (FDA Neurontin prescribing information; and the FDA's gabapentinoid respiratory depression safety communication).

What to tell patients

Both agents can cause drowsiness, and using them on the same evening, especially in the first few nights of a new combination, may produce more sedation than either alone. Patients should avoid driving or operating machinery within several hours of using both on the same evening and should report next-morning grogginess, unusual vivid dreams, or feeling mentally foggy for an extended period after waking. Alcohol should be avoided on evenings when either drug is used, since it independently worsens gabapentin's sedating effects and independently blunts the GH response that CJC-1295 is meant to stimulate.

Patients should tell every prescriber involved, including a neurologist or pain specialist managing gabapentin, about any peptide use, since GH secretagogues can affect glucose metabolism, renal function, and sleep architecture, all of which are relevant to decisions made by clinicians who are not managing the peptide directly.

When to seek urgent care

Witnessed pauses in breathing during sleep, new or worsening difficulty breathing, unusual falls, syncope, or a seizure in someone with a previously stable seizure disorder all warrant same-day contact with a clinician, and witnessed breathing pauses warrant emergency evaluation rather than a routine call. These symptoms occurring after a new or recently changed peptide protocol should be treated as a reason for prompt re-evaluation rather than something to monitor at home.

What is established, what is plausible, and what is not known

Established: neither drug is metabolized by hepatic CYP450 enzymes, gabapentin's clearance is entirely renal, gabapentin's own label documents dose-dependent sedation and a class-wide respiratory depression warning for gabapentinoids combined with other CNS depressants, and CJC-1295 has no FDA-approved indication and is used as a compounded, off-label agent.

Plausible but unproven: that CJC-1295 meaningfully raises GFR in people who are not GH-deficient, that this could modestly lower steady-state gabapentin levels over months of use, and that GHRH signaling produces a noticeable sedating or sleep-deepening effect in humans at typical compounded doses.

Not established: any direct pharmacokinetic or pharmacodynamic interaction data from a study that actually combined CJC-1295 and gabapentin in humans. None currently exists. Everything above the level of "neither drug uses CYP450 enzymes" is inference from the separate pharmacology of each agent, and a prescriber or pharmacist reviewing this combination for a specific patient should verify current label language and any newer literature directly rather than relying on secondhand summaries, including this one.